Premium
Preparation of [ 188 Re]rhenium sulfide suspension and its biodistribution following intra‐tumor injection in mice
Author(s) -
Junfeng Yu,
Duanzhi Yin,
Xiaofeng Min,
Zili Guo,
Jiong Zhang,
Yongxian Wang,
Knapp F. F.
Publication year - 1999
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/(sici)1099-1344(199903)42:3<233::aid-jlcr182>3.0.co;2-r
Subject(s) - rhenium , chemistry , sulfide , biodistribution , radiochemistry , technetium , suspension (topology) , nuclear chemistry , in vitro , inorganic chemistry , biochemistry , organic chemistry , mathematics , homotopy , pure mathematics
[ 188 Re]Rhenium sulfide suspension was prepared by the reaction of Na 2 S 2 O 3 and KReO 4 containing Na 188 ReO 4 in acid solution and assessed for its applicability in tumor treatment by the techniques of radioisotope interventional therapy. The reaction conditions such as the concentration ratio of Na 2 S 2 O 3 to KReO 4 , heating time, ultrasonic time were optimized. The radiochemical yield of [ 188 Re]Rhenium sulfide suspension is more than 96% and in vitro stability studies demonstrated that more than 99% of the 188 Re remained in sulfide form over a 72 hrs period. The main particle size after various ultrasonic times is 1–5 μm. [ 188 Re]Rhenium sulfide suspension was injected into tumors and the tumor‐bearing mice were killed after some time to determine the retention of 188 Re in tumor and the leakage to different organs by γ counter. The mean retention percentages of 188 Re in tumors were 83·08±13·71%, 83·92±9·79%, 80·23±3·82% and 78·75±3·02% at 1 h, 24, 48 and 72 hrs respectively. After 72 hrs the highest activity outside the tumors was in the liver, spleen and the kidneys. Our preliminary results indicated that [ 188 Re]Rhenium sulfide suspension may be an effective radiopharmaceutical for tumor treatment by the techniques of radioisotope interventional therapy. Copyright © 1999 John Wiley & Sons, Ltd.